BRPI0408704A - benzil-piridazinonas como inibidores de transcriptase reversa - Google Patents

benzil-piridazinonas como inibidores de transcriptase reversa

Info

Publication number
BRPI0408704A
BRPI0408704A BRPI0408704-6A BRPI0408704A BRPI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A BR PI0408704 A BRPI0408704 A BR PI0408704A
Authority
BR
Brazil
Prior art keywords
reverse transcriptase
formula
compounds
transcriptase inhibitors
pyridazinones
Prior art date
Application number
BRPI0408704-6A
Other languages
English (en)
Inventor
James Patrick Dunn
Brian William Dymock
Taraneh Mirzadegan
Eric Brian Sjogren
Steven Swallow
Zachary Kevin Sweeney
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0408704A publication Critical patent/BRPI0408704A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22—Nitrogen and oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

"BENZIL-PIRIDAZINONAS COMO INIBIDORES DE TRANSCRIPTASE REVERSA". Esta invenção refere-se a derivados de piridazinonas inusitados, da fórmula I, onde R¬ 1¬-R¬ 4¬, R¬ 7¬, R¬ 8¬ e X¬ 1¬ são como definidos no sumário, e seus sais e solvatos farmaceuticamente aceitáveis, e métodos para inibir ou modular a trasncriptase reversa do Vírus da Imunodeficiência Humana (HIV) com compostos da fórmula I, composições farmacêuticas que contêm os compostos da fórmula I misturados com pelo menos um solvente, veículo ou excipiente, e processos para preparar compostos da fórmula I. Os compostos são úteis para tratar distúrbios nos quais HIV e vírus geneticamente relacionados estão implicados.
BRPI0408704-6A 2003-03-24 2004-03-17 benzil-piridazinonas como inibidores de transcriptase reversa BRPI0408704A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45714403P 2003-03-24 2003-03-24
PCT/EP2004/002736 WO2004085406A1 (en) 2003-03-24 2004-03-17 Benzyl-pyridazinons as reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0408704A true BRPI0408704A (pt) 2006-03-07

Family

ID=33098202

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408704-6A BRPI0408704A (pt) 2003-03-24 2004-03-17 benzil-piridazinonas como inibidores de transcriptase reversa

Country Status (13)

Country Link
US (1) US7189718B2 (pt)
EP (1) EP1608629A1 (pt)
JP (1) JP4485520B2 (pt)
KR (1) KR20050119652A (pt)
CN (1) CN100469769C (pt)
AR (1) AR043674A1 (pt)
AU (1) AU2004224191A1 (pt)
BR (1) BRPI0408704A (pt)
CA (1) CA2518823A1 (pt)
MX (1) MXPA05010081A (pt)
RU (1) RU2344128C2 (pt)
TW (1) TW200505453A (pt)
WO (1) WO2004085406A1 (pt)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
ES2232306B1 (es) * 2003-11-10 2006-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
CA2559552A1 (en) * 2004-03-23 2005-09-29 F. Hoffmann-La Roche Ag Benzyl-pyridazinone derivatives as non-nucleoside reverse transcriptase inhibitors
CA2563225A1 (en) * 2004-04-15 2005-10-27 F. Hoffmann-La Roche Ag Process for preparing pyridazinone compounds
WO2006040527A1 (en) * 2004-10-16 2006-04-20 Astrazeneca Ab Process for making phenoxy benzamide compounds
GB0423042D0 (en) * 2004-10-16 2004-11-17 Astrazeneca Ab Chemical process
CA2600759A1 (en) * 2005-03-24 2006-09-28 F. Hoffmann-La Roche Ag 1,2,4-triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
AU2006298853A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag NNRT inhibitors
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
GB0610680D0 (en) * 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
CL2007002105A1 (es) * 2006-07-21 2008-02-22 Hoffmann La Roche Compuestos derivados de 2-[3-(3-cianofenoxi)(fenoxi o fenilsulfanil)]-n-fenil acetamida, inhibidores de la transcriptasa inversa del vih; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar u
PL2057125T3 (pl) 2006-08-16 2011-09-30 Hoffmann La Roche Nienukleozydowe inhibitory odwrotnej transkryptazy
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
BRPI0809617A2 (pt) * 2007-03-29 2014-09-16 Hoffmann La Roche Inibidores não-nucleosídicos da transcriptase reversa
MX2009010932A (es) * 2007-04-09 2009-10-29 Hoffmann La Roche Inhibidores no nucleosidos de transcriptasa inversa.
EP2148879B1 (en) 2007-04-23 2012-11-28 Janssen Pharmaceutica, N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
EP2148873B1 (en) 2007-04-23 2012-08-29 Janssen Pharmaceutica, N.V. 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists
JP5167350B2 (ja) * 2007-05-30 2013-03-21 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド系逆転写酵素阻害剤
KR20100039348A (ko) * 2007-06-22 2010-04-15 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역 전사효소 억제제로서 우레아 및 카바메이트 유도체
ES2524787T3 (es) * 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
JP5539216B2 (ja) 2007-11-20 2014-07-02 メルク・シャープ・アンド・ドーム・コーポレーション 非ヌクレオシド系逆転写酵素阻害剤
US8877816B2 (en) * 2007-11-21 2014-11-04 Decode Genetics Ehf 4-(or 5-) substituted catechol derivatives
RU2495878C2 (ru) * 2007-12-21 2013-10-20 Ф.Хоффманн-Ля Рош Аг Гетероциклические антивирусные соединения
JP5457450B2 (ja) 2008-07-31 2014-04-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 迅速解離性ドーパミン２受容体拮抗薬としてのピペラジン−１−イル−トリフルオロメチル−置換−ピリジン
CN102171204B (zh) 2008-10-02 2014-08-20 旭化成制药株式会社 8位取代异喹啉衍生物及其用途
DK2924034T3 (en) 2010-03-30 2017-02-06 Merck Canada Inc PHARMACEUTICAL COMPOSITION CONTAINING A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR
CN102731410B (zh) * 2012-07-06 2014-07-30 山东大学 一种哒嗪类hiv-1逆转录酶抑制剂的制备与应用
JO3470B1 (ar) 2012-10-08 2020-07-05 Merck Sharp & Dohme مشتقات 5- فينوكسي-3h-بيريميدين-4-أون واستخدامها كمثبطات ناسخ عكسي ل hiv
AU2015241247B2 (en) 2014-04-01 2017-09-14 Merck Sharp & Dohme Llc Prodrugs of HIV reverse transcriptase inhibitors
AU2017346871B2 (en) 2016-10-18 2023-08-03 Madrigal Pharmaceuticals, Inc. Methods of treating liver disorders or lipid disorders with a THR-beta agonist
CN109053693B (zh) * 2018-09-20 2021-02-05 顺毅股份有限公司 哒嗪胺类化合物的制备及其应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
US4211771A (en) 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4780480A (en) 1983-07-14 1988-10-25 Syntex (U.S.A.) Inc. Aroyl benzofuran and benzothiophene acetic and propionic acids
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5783593A (en) 1993-11-04 1998-07-21 Abbott Laboratories Inhibitors of squalene synthetase and protein farnesyltransferase
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
ATE255564T1 (de) 1994-09-26 2003-12-15 Shionogi & Co Imidazolderivat
CA2212645A1 (en) 1995-02-10 1996-08-15 Damien John Dunnington Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection
TR199700801T1 (xx) 1995-02-16 1998-03-21 F. Hoffmann-La Roche Ag İnterleukin 12 kullanılarak angiogenesisin önlenmesi.
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
CA2225668A1 (en) 1995-06-30 1997-01-23 Damien John Dunnington Use of stat 6 sh2 domain specific compounds to treat allergic reactions
WO1997002024A1 (en) 1995-06-30 1997-01-23 Smithkline Beecham Corporation Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
CA2205757C (en) 1996-05-30 2006-01-24 F. Hoffmann-La Roche Ag Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii)
RU2000129671A (ru) * 1998-04-27 2004-02-20 Сантр Насьональ Де Ля Решерш Сьентифик (Fr) Производные 3-(амино- или аминоалкил) пиридинона и их применение для лечения болезней, связанных с ВИЧ
AU4884701A (en) 2000-05-12 2001-11-20 Kissei Pharmaceutical Co. Ltd. Malonanilic acid derivatives, medicinal compositions containing the same and usethereof
GB0024795D0 (en) 2000-10-10 2000-11-22 Hoffmann La Roche Pyrazole derivatives for the treatment of viral diseases
RS51166B (sr) 2001-04-10 2010-10-31 Pfizer Inc. Derivati pirazola za tretiranje hiv
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤

Also Published As

Publication number Publication date
AU2004224191A1 (en) 2004-10-07
JP4485520B2 (ja) 2010-06-23
RU2344128C2 (ru) 2009-01-20
AR043674A1 (es) 2005-08-03
US7189718B2 (en) 2007-03-13
JP2006521310A (ja) 2006-09-21
US20040198736A1 (en) 2004-10-07
TW200505453A (en) 2005-02-16
RU2005132630A (ru) 2006-07-27
WO2004085406A1 (en) 2004-10-07
CN100469769C (zh) 2009-03-18
CN1764649A (zh) 2006-04-26
CA2518823A1 (en) 2004-10-07
EP1608629A1 (en) 2005-12-28
MXPA05010081A (es) 2005-11-23
KR20050119652A (ko) 2005-12-21

Similar Documents

Publication Publication Date Title
BRPI0408704A (pt) benzil-piridazinonas como inibidores de transcriptase reversa
BRPI0407591A (pt) inibidores de transcriptase reversa de não-nucleosìdeo
BRPI0408767A (pt) inibidores de transcriptase reversa não-nucleosìdeos i para o tratamento de doenças mediadas pelo hiv
BR0208811A (pt) Derivados de pirazol para tratamento de hiv
BR0316081A (pt) Derivados de 2-piridona como inibidores de elastase de neutrófilo
BR0209267A (pt) Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
BR0315912A (pt) Compostos pirimìdicos com atividade antiproliferativa (ii)
BRPI0508107A (pt) derivados de indazol e composições farmacêuticas contendo os mesmos
BR0313041A (pt) Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
BR0312271A (pt) compostos, composições e seus usos para o tratamento de infecções por flaviviridae
BR0210350A (pt) Nucleosìdeos 4'-substituìdos
BRPI0215312B8 (pt) composto, uso de um composto, composição farmacêutica, e processo para a preparação de um composto
BR0212378A (pt) Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
NI200700102A (es) Derivados de indol tetraciclicos como agentes antiviricos
BRPI0510059B8 (pt) inibidores da transcriptase reversa não-nucleosídica e seus usos
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
BRPI0507675A (pt) derivados de 2'-c-metil nucleosìdeo
ECSP067076A (es) Derivados de pirimidina urea como inhibidores de la quinasa
NO20010743L (no) Antivirale indoloksoacetyl-piperazin-derivater
BRPI0515885A (pt) derivados de ftalazinona, sua preparação e uso como agentes farmacêuticos
BRPI0415759A (pt) compostos de pirimidin-4-il-3,4-tiona e uso dos mesmos na terapia
BRPI0407976A (pt) tetrahidroisoquinolinas substituìdas em 2,5 e 2,6 para uso como moduladores de 5-ht6
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
BRPI0514032A (pt) composto, sais farmaceuticamente aceitáveis do mesmo, diastereÈmeros, enanciÈmeros ou misturas do mesmo, uso de um composto, composição farmacêutica, método para a terapia de depressão em um animal de sangue quente, e, processo para preparar um composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.